Skip to main content
SpringerLink
Log in

Safety of COVID-19 mRNA vaccine first booster doses among immunocompromised persons

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Hause AM, et al. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ?12 Years with Presumed Immunocompromise Status ? United States, January 12, 2022?March 28, 2022 Morbidity and Mortality Weekly Report : 20 Jul 2022. Available from: URL: https://doi.org/10.15585/mmwr.mm7128a3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Safety of COVID-19 mRNA vaccine first booster doses among immunocompromised persons. Reactions Weekly 1917, 11 (2022). https://doi.org/10.1007/s40278-022-19882-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-19882-1

Search

Navigation